Professor Ioanna Gouni-Berthold, University of Cologne, Germany
Since I last discussed cinical trial data on novel Lp(a)-targeting medicines in development – antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs) and small molecules –some exciting new data have been reported and important new studies are underway.
